- Home
- REPL vs TBLD Comparison
REPL vs TBLD Comparison
Compare REPL & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- TBLD
- Stock Information
- Founded
- REPL 2015
- TBLD 2021
- Country
- REPL United States
- TBLD United States
- Employees
- REPL 479
- TBLD N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- TBLD Investment Managers
- Sector
- REPL Health Care
- TBLD Finance
- Exchange
- REPL Nasdaq
- TBLD Nasdaq
- Market Cap
- REPL 239.0M
- TBLD 633.0M
- IPO Year
- REPL 2018
- TBLD N/A
- Fundamental
- Price
- REPL $3.15
- TBLD $19.44
- Analyst Decision
- REPL Buy
- TBLD
- Analyst Count
- REPL 10
- TBLD 0
- Target Price
- REPL $8.25
- TBLD N/A
- AVG Volume (30 Days)
- REPL 9.2M
- TBLD 102.0K
- Earning Date
- REPL 08-07-2025
- TBLD 01-01-0001
- Dividend Yield
- REPL N/A
- TBLD 6.44%
- EPS Growth
- REPL N/A
- TBLD N/A
- EPS
- REPL N/A
- TBLD N/A
- Revenue
- REPL N/A
- TBLD N/A
- Revenue This Year
- REPL N/A
- TBLD N/A
- Revenue Next Year
- REPL N/A
- TBLD N/A
- P/E Ratio
- REPL N/A
- TBLD N/A
- Revenue Growth
- REPL N/A
- TBLD N/A
- 52 Week Low
- REPL $2.68
- TBLD $15.80
- 52 Week High
- REPL $17.00
- TBLD $20.55
- Technical
- Relative Strength Index (RSI)
- REPL 24.82
- TBLD 50.62
- Support Level
- REPL $2.68
- TBLD $19.35
- Resistance Level
- REPL $3.85
- TBLD $20.55
- Average True Range (ATR)
- REPL 0.80
- TBLD 0.50
- MACD
- REPL -1.03
- TBLD -0.06
- Stochastic Oscillator
- REPL 4.45
- TBLD 37.64
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.